Cart
sales@molnova.com
tert-Butyl ((3-hydroxyazetidin-3-yl)methyl)carbamate
CAS No. 1035351-07-5
tert-Butyl ((3-hydroxyazetidin-3-yl)methyl)carbamate( —— )
Catalog No. M17122 CAS No. 1035351-07-5
tert-Butyl ((3-hydroxyazetidin-3-yl)methyl)carbamate is an active biochemical agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 39 | In Stock |
|
| 5MG | 39 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 115 | In Stock |
|
| 50MG | 184 | In Stock |
|
| 100MG | 269 | In Stock |
|
| 200MG | 383 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Nametert-Butyl ((3-hydroxyazetidin-3-yl)methyl)carbamate
-
NoteResearch use only, not for human use.
-
Brief Descriptiontert-Butyl ((3-hydroxyazetidin-3-yl)methyl)carbamate is an active biochemical agent.
-
Descriptiontert-Butyl ((3-hydroxyazetidin-3-yl)methyl)carbamate is an active biochemical agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1035351-07-5
-
Formula Weight202.25
-
Molecular FormulaC9H18N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1NCC1(CNC(=O)OC(C)(C)C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Ethyl 6-hydroxyhexan...
Ethyl 6-hydroxyhexanoate can be used to synthesize 2-Bu suberic acid.
-
Kaempferol-3-O-alpha...
Kaempferol-3-O-α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyl-(1→2)-β-D-glucopyranoside shows antioxidant activity.
-
Syk Inhibitor II hyd...
The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus.
